Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire (Lynch-SCAN)

University of British Columbia

Status: Enrolling

Conditions: Endometrial Cancer; Lynch Syndrome

Treatments: Combination Product: Vaginal DNA swab, microbiome swab and pH test

Study type: Interventional

Funder types: Other

Identifiers

NCT07194551

H24-00911

Details and patient eligibility

About

The goal of this study is to find out if self-collected vaginal swabs can be used to detect early signs of uterine cancer or related conditions in people with Lynch syndrome (LS) who still have their uterus. The study also tests if people with LS are willing and able to collect these samples themselves and whether they find the process acceptable.

The main questions this study asks are:

• Will people with LS take part in self-collection of vaginal samples, and do they find it acceptable?
• Can vaginal DNA mutations predict cancer risk or match results from other genetic or biopsy testing?
• Can a cancer risk model used in the general population also help identify risk in people with LS?

Participants will:

• Answer a health questionnaire about lifestyle and symptoms
• Collect their own vaginal swabs and measure their vaginal pH at home using a self-collection kit
• Complete short surveys around the time of self-collection and at the end of the study

Enrollment: 30 estimated patients

Sex: Female

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with Lynch syndrome (confirmed by genetic testing).
• Have an intact uterus.
• Age 30 years or older.

Exclusion criteria

• History of endometrial cancer or endometrial hyperplasia.
• History of pelvic radiation or endometrial ablation.
• Pregnant at the time of study enrolment or during the study.

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Vaginal self-collection

Experimental group

Description:

Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Participants with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.

Treatment:

Combination Product: Vaginal DNA swab, microbiome swab and pH test